Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cancer disease
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Magazines
Downloads
Videos

Refine by
Date

  • Older

Cancer Disease Articles & Analysis

294 news found

Advanced Tumor Organoid & CAF Co-culture Service to Accelerate Cancer Research

Advanced Tumor Organoid & CAF Co-culture Service to Accelerate Cancer Research

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development of more effective cancer therapies. ...

ByCD Bioparticles


Neutrophils and Lactoferrin a key duo in inflammation

Neutrophils and Lactoferrin a key duo in inflammation

This limitation has made it difficult to fully grasp their contribution to health and disease. Recent scientific progress is now changing this picture. Researchers have developed innovative ways to study neutrophils by focusing on one of their most important components: lactoferrin. ...

ByBertin Technologies


Creative Proteomics Introduces Central Carbon Metabolism Analysis Service to Accelerate Metabolic Research   

Creative Proteomics Introduces Central Carbon Metabolism Analysis Service to Accelerate Metabolic Research  

Researchers have long recognized the importance of CCM in regulating cellular function and contributing to the understanding of various diseases, including cancer, diabetes, and neurodegenerative disorders. ...

ByCreative Proteomics


Alfa Chemistry Expands Pharmaceutical Product Portfolio: Introducing PROTAC Building Blocks, Nucleosides, Intermediates, and APIs

Alfa Chemistry Expands Pharmaceutical Product Portfolio: Introducing PROTAC Building Blocks, Nucleosides, Intermediates, and APIs

These include E3 ligase ligands such as CRBN and VHL, and linkers which act as a mediator between target proteins and ligases to broaden the therapeutic options (especially in the treatment of cancer and neurodegenerative diseases). Nucleosides, the building blocks of nucleic acids, aren’t only simple building blocks for RNA and DNA. In medical ...

ByAlfa Chemistry


Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody Solutions

Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody Solutions

During the event, the team demonstrated their pipeline from phage construction to screening and their masterpiece in discovering PTM specific antibodies, anti-idiotype antibodies, which gives researchers an edge when looking to discover novel targets in immunotherapy, cancer, and infectious diseases. Another hot topic during the festival was the growing interest ...

ByCreative Biolabs


SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research

SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s ...

BySOPHiA Genetics


Being Green and Sustainable: Alfa Chemistry Provides Biobased Pharmaceutical Chemicals, Plasticizers, and Biofuels   

Being Green and Sustainable: Alfa Chemistry Provides Biobased Pharmaceutical Chemicals, Plasticizers, and Biofuels  

Historically, natural products have played a pivotal role in traditional healing systems, and modern science continues to exploit these compounds for their therapeutic potentials, particularly in combating cancerous and infectious diseases. Pharmaceutical chemicals, based on their source, are categorized as biobased, synthetic, or semi-synthetic. ...

ByAlfa Chemistry


Alfa Chemistry Expands Portfolio with Diverse Alkaloids-Related Natural Products for Health, Nutrition Enhancement

Alfa Chemistry Expands Portfolio with Diverse Alkaloids-Related Natural Products for Health, Nutrition Enhancement

Their versatility extends to applications in cancer treatment and wound healing, making them a significant focus of biotechnological research. Antibiotics, natural products predominantly produced by microorganisms, hold a crucial role in combating infectious diseases. Alfa Chemistry’s portfolio includes a diverse collection of antibiotics used in medical ...

ByAlfa Chemistry


CD BioGlyco Updated Its Glycoprotein Quantification Service Recently

CD BioGlyco Updated Its Glycoprotein Quantification Service Recently

This enhancement aims to offer more precise and comprehensive glycoprotein analysis, catering to the growing demands in the fields of biomedical research, disease biomarker discovery, and therapeutic development. Protein glycosylation, a major post-translational modification, significantly impacts protein folding, stability, and activity. Changes in glycoprotein abundance and ...

ByCD BioGlyco.


Tempus Announces the Clinical Launch of its MRD Testing Portfolio

Tempus Announces the Clinical Launch of its MRD Testing Portfolio

The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual disease or early cancer recurrence and monitor for immunotherapy treatment response, providing valuable insights to inform patient management strategies. ...

ByTempus


Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology

Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur – Oncovita laboratory is to design and develop vaccine candidates through to proof of concept in humans. ...

ByOncoVITA


Why small molecule development?

Why small molecule development?

Small molecule drugs have a proven track record of success in treating a wide range of diseases, including cancer, cardiovascular disorders, and infectious diseases. By leveraging the potential of small molecules, our clients can benefit from: Targeted Therapies - Small molecules can be designed to selectively modulate specific biological ...

ByProtheragen-ING


CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays

CD BioSciences Announces Comprehensive Range of Nervous System Tissue Microarrays

This comprehensive offering provides researchers with a powerful tool for studying various neurological disorders, including brain tumors, head and neck cancers, and neurodegenerative diseases. For example, Multiple Sites of Normal Brain Tissue Microarray, 80 Cases, 26 Cores (Catalog NO. ...

ByCD BioSciences


Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

Inhibition of this enzyme can produce therapeutic effects in disease states like cancer, rheumatoid arthritis, and cardiovascular disease. ...

ByCreative Enzymes


ATMP Sterility Testing

ATMP Sterility Testing

Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. ...

ByParticle Measuring Systems (PMS)


CD Genomics Revolutionizes TCR-Seq Elevating Immune Repertoire Profiling to New Heights

CD Genomics Revolutionizes TCR-Seq Elevating Immune Repertoire Profiling to New Heights

This critical information holds immense potential in unraveling immune responses, gaining insights into autoimmune diseases, advancing cancer immunotherapy, and propelling vaccine development. ...

ByCD Genomics


CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

This empowers researchers and pharmaceutical entities to tailor antibody therapies for an extensive array of diseases, ranging from cancer to autoimmune disorders. The Antibody Drug Design Services streamline development timelines, concurrently optimizing costs and increasing the likelihood of success. By utilizing predictive binding affinity analyses and ...

ByCD ComputaBio


CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

Antibody-based therapies have witnessed unprecedented success in treating a wide array of diseases, from cancer to autoimmune disorders. However, the traditional antibody discovery process is labor-intensive, time-consuming, and costly. ...

ByCD ComputaBio


CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems   

CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems  

CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically modifying a patient's own immune cells to recognize and attack cancer cells more efficiently. By engineering these cells to express specific receptors on their surface, they acquire enhanced targeting capabilities against malignant cells, giving rise ...

ByCD Formulation


Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc

Semper Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen Bio Inc

” Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders with the aim of addressing the significant unmet needs of ...

ByTevogen Bio

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT